Gene Therapy Market Predicted to Reach $10.1 Billion by 2032 with 18.5% CAGR

In 2021, the global gene therapy market is expected to be worth $1.55 billion USD. The market is expected to increase at an 18.5% CAGR from US$ 1.85 billion in 2022 to US$ 10.1 billion by 2032.

Gene therapy is a transformative field within the biotechnology and healthcare sectors, offering the potential to treat a wide range of genetic disorders and diseases by modifying or replacing faulty genes. This innovative approach holds promise for addressing previously incurable conditions and improving patient outcomes. The gene therapy market has witnessed substantial growth in recent years as advancements in biotechnology, improved understanding of genetics, and regulatory approvals have paved the way for the development and commercialization of gene-based therapies.

Get Free Sample Copy of This Report-

Gene Therapy Market Demand & Supply Trends

  1. Growing Prevalence of Genetic Disorders: The increasing incidence of genetic disorders and rare diseases has fueled the demand for gene therapy. Patients suffering from conditions like hemophilia, muscular dystrophy, and certain forms of cancer can benefit from targeted gene-based treatments.
  2. Cancer Immunotherapy: Gene therapy has emerged as a key component of cancer immunotherapy. CAR-T cell therapies, which involve genetically modifying a patient’s own immune cells to target cancer, have gained prominence in the treatment of hematologic malignancies.
  3. Expanding Therapeutic Applications: Gene therapy is being explored for a wide range of therapeutic applications, including neurological disorders, ophthalmic diseases, cardiovascular conditions, and infectious diseases. This diversification of applications contributes to market growth.
  4. Investment and Funding: The gene therapy sector has attracted significant investment from both public and private sources. Funding for research and development has accelerated the pace of innovation and clinical trials.
  5. Regulatory Approvals: The approval of gene therapies by regulatory authorities, such as the U.S. FDA and the European Medicines Agency (EMA), has provided a clear pathway for commercialization. This has encouraged pharmaceutical companies to invest in gene therapy programs.
  6. Advancements in Gene Editing Technologies: The development of precise gene editing technologies like CRISPR-Cas9 has opened up new possibilities in gene therapy. These technologies enable more targeted and efficient gene modifications.

Gene Therapy Market Current Issues and Challenges

  • High Costs: Gene therapies are often associated with high development and treatment costs. This can pose challenges for patient access and reimbursement, particularly in healthcare systems with budget constraints.
  • Safety Concerns: Ensuring the safety of gene therapies is a paramount concern. Adverse events or unintended consequences of gene editing can have serious consequences. Rigorous safety assessments and monitoring are essential.
  • Long-Term Efficacy: The long-term efficacy of gene therapies is an ongoing question. Monitoring patient outcomes and assessing the durability of treatment effects is critical for establishing the value of these therapies.
  • Limited Manufacturing Capacity: The production of gene therapies can be complex and time-consuming. Limited manufacturing capacity can hinder the availability of these treatments, particularly for rare diseases.
  • Ethical and Regulatory Issues: Ethical considerations surrounding gene editing and germline modifications continue to be debated. Regulatory frameworks must evolve to address these ethical challenges.
  • Patient Access: Ensuring equitable patient access to gene therapies is a pressing challenge. Addressing affordability, reimbursement, and access disparities is essential for realizing the full potential of these treatments.

Competitive Landscape

The global gene therapy market is characterized by intense competition, with a select few major players holding significant market share. Notable companies, including Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., dominate this dynamic market. These industry leaders employ various strategic initiatives, including collaborations, acquisitions, and the introduction of advanced products, to secure their positions in the global gene therapy market.

Recent Developments:

  1. Collaborative Initiatives for Rare Diseases: In October 2021, a collaboration involving the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations was announced. This collaborative effort aims to accelerate the development of gene therapies tailored for the 30 million Americans afflicted by rare diseases. Such initiatives are expected to drive increased demand for gene therapy treatments.
  2. BioMarin Pharmaceutical Inc.’s Updates: In February 2022, BioMarin Pharmaceutical Inc. provided updates on its investigational gene therapy programs in clinical development. The Food and Drug Administration (FDA) had issued additional requests for information to the company to address the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307, which had been imposed in September 2021. These developments underscore the regulatory rigor associated with gene therapy programs.
  3. Novartis’ Strategic Acquisition: In December 2021, Novartis made a significant acquisition by purchasing Gyroscope Therapeutics. This addition brought a one-time gene therapy into Novartis’ portfolio, holding the potential to revolutionize the treatment of geographic atrophy, a leading cause of blindness. This strategic move positions Novartis to expand its footprint in the gene therapy market.
  4. FDA Approval for Abecma: In March 2021, the US Food and Drug Administration granted approval for Abecma (idecabtagene vicleucel), a cell-based gene therapy. This milestone marked a significant achievement in the gene therapy field, as Abecma became the first FDA-approved cell-based gene therapy for the treatment of multiple myeloma in adult patients who have not responded to or have experienced disease relapse after undergoing at least four prior lines of therapy. This approval underscores the therapeutic potential of gene-based treatments.

Key Segments Covered in Gene Therapy Industry Research

  • By Product :
    • Yescarta-based
    • Kymriah-based
    • Luxturna-based
    • Strimvelis-based
    • Gendicine
    • Others
  • By Application :
    • Ophthalmology
    • Oncology
    • Adenosine Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID)
  • By Region :
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia
    • MEA

Get Customization on this Report for Specific Research Solutions –

The gene therapy market holds immense promise for revolutionizing the treatment of genetic disorders and other diseases. Demand is driven by the increasing prevalence of genetic conditions, advancements in therapeutic applications, investment and funding, regulatory approvals, and breakthroughs in gene editing technologies. However, challenges related to cost, safety, long-term efficacy, manufacturing capacity, ethics, and patient access must be addressed to ensure the continued growth and success of the gene therapy sector.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232